Effexor Ruling Gives Plaintiffs Path Against No-AG Deals
A district court's Monday ruling that no-authorized-generic agreements between pharmaceutical companies don't have to include cash to count as pay-for-delay settlements under federal antitrust law offers a possible roadmap for pursuing...To view the full article, register now.
Already a subscriber? Click here to view full article